129 related articles for article (PubMed ID: 26829212)
1. RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.
Szabo A; Fekete T; Koncz G; Kumar BV; Pazmandi K; Foldvari Z; Hegedus B; Garay T; Bacsi A; Rajnavolgyi E; Lanyi A
Cell Signal; 2016 May; 28(5):335-347. PubMed ID: 26829212
[TBL] [Abstract][Full Text] [Related]
2. P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b.
Naffa R; Vogel L; Hegedűs L; Pászty K; Tóth S; Kelemen K; Singh N; Reményi A; Kállay E; Cserepes M; Tóvári J; Grusch M; Enyedi Á
Cells; 2020 May; 9(5):. PubMed ID: 32414111
[TBL] [Abstract][Full Text] [Related]
3. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract][Full Text] [Related]
4. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
[TBL] [Abstract][Full Text] [Related]
5. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
[TBL] [Abstract][Full Text] [Related]
6. ANP inhibits TNF-alpha-induced endothelial MCP-1 expression--involvement of p38 MAPK and MKP-1.
Weber NC; Blumenthal SB; Hartung T; Vollmar AM; Kiemer AK
J Leukoc Biol; 2003 Nov; 74(5):932-41. PubMed ID: 12960255
[TBL] [Abstract][Full Text] [Related]
7. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
8. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
9. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of extracellular signal-regulated kinase (ERK) signaling participates in repression of nuclear factor (NF)-kappaB activity by glucocorticoids.
Bladh LG; Johansson-Haque K; Rafter I; Nilsson S; Okret S
Biochim Biophys Acta; 2009 Mar; 1793(3):439-46. PubMed ID: 19110010
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory effects of glutamine on LPS-stimulated human dental pulp cells correlate with activation of MKP-1 and attenuation of the MAPK and NF-κB pathways.
Kim DS; Shin MR; Kim YS; Bae WJ; Roh DH; Hwang YS; Kim EC
Int Endod J; 2015 Mar; 48(3):220-8. PubMed ID: 24766418
[TBL] [Abstract][Full Text] [Related]
12. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells.
Chen TH; Kao YC; Chen BC; Chen CH; Chan P; Lee HM
Eur J Pharmacol; 2006 Jul; 541(3):138-46. PubMed ID: 16765938
[TBL] [Abstract][Full Text] [Related]
13. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
15. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
16. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
17. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
18. RIG-I acts as a tumor suppressor in melanoma via regulating the activation of the MKK/p38MAPK signaling pathway.
Guo R; Lu SY; Ma JX; Wang QL; Zhang L; Tang LY; Shen Y; Shen CL; Wang JJ; Lu LM; Wang ZG; Zhang HX
Hum Cell; 2022 Jul; 35(4):1071-1083. PubMed ID: 35416622
[TBL] [Abstract][Full Text] [Related]
19. Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways.
Chen Y; Li H; Li M; Niu S; Wang J; Shao H; Li T; Wang H
J Ethnopharmacol; 2017 Mar; 200():165-173. PubMed ID: 28232127
[TBL] [Abstract][Full Text] [Related]
20. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]